← Back to all trials
Active Not Recruiting
NCT07923240
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Conditions: Metabolic Abnormalities, Obesity & Overweight, Cerebral Atherosclerosis, Cerebrovascular Disease
Sex: All
Ages: 50 Years – 74 Years
Healthy volunteers: No
Phase: PHASE4
Enrollment: 30
Sponsor: Research Center of Neurology, Russia
Location: Russian Center of Neurology and Neurosciences Moscow Moscow
Summary
We aim to elucidate the metabolic and neuroactive properties of sequential Mexidol therapy in patients with and without cerebrometabolic disorders using blood biomarkers, anthropometry and brain functional MRI (task- and rest).
Eligibility Criteria
Inclusion Criteria:
* cerebrovascular disease (I67.8) and/or cerebral atherosclerosis (I67.2)
* metabolic disorders (diabetes and/or BMI 27 or higher) for Group1
* no metabolic disorders - for Group 2
Exclusion Criteria:
* decompensated somatic pathology
* history of neoplasia
* acute stroke/myocardial infarction
Source: ClinicalTrials.gov (NCT07923240). StuddyBuddy aggregates publicly available trial information.
